Suchergebnisse - "Özgüroğlu, Mustafa"

PubPharm (181)

1

Tolerability of Olaparib Combined with Abiraterone in Patients with Metastatic Castration-resistant Prostate Cancer : Further Results from the Phase 3 PROpel Trial

enthalten in: European urology oncology | 2024

von Saad, F. | Armstrong, A. | Oya, M. | +16

2

Prostate-specific antigen (PSA) decline with apalutamide therapy is associated with longer survival and improved outcomes in individuals with metastatic prostate cancer : a plain language summary of the TITAN study

enthalten in: Future oncology (London, England) | 2024

von Chowdhury, S. | Bjartell, A. | Agarwal, N. | +15

3

Symptomatic Pneumonitis With Durvalumab After Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC

enthalten in: JTO clinical and research reports | 2024

von Vansteenkiste, J. | Naidoo, J. | Faivre-Finn, C. | +13

4

Durvalumab ± Tremelimumab + Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN) : Outcomes by PD-L1 Expression and Tissue Tumor Mutational Burden

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2024

von Paz-Ares, L. | Garassino, M. | Chen, Y. | +19

CommentIn: Clin Cancer Res. 2024 Feb 16;30(4):652-654. - PMID 38085269

5

Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in BRCA1 and/or BRCA2 in the PROfound Trial

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2024

von Mateo, J. | de Bono, J. | Fizazi, K. | +20

6

Avelumab Versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients With High-Expression Programmed Death-Ligand 1-Positive Metastatic NSCLC : Primary Analysis From the Phase 3 JAVELIN Lung 100 Trial

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2024

von Reck, M. | Barlesi, F. | Yang, J. | +15

7

Targeted treatment for unresectable EGFR mutation-positive stage III non-small cell lung cancer : Emerging evidence and future perspectives

enthalten in: Lung cancer (Amsterdam, Netherlands) | 2024

von Kato, T. | Casarini, I. | Cobo, M. | +5

8

Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130) : final overall survival analysis from a randomised, controlled, phase 3 study

enthalten in: The Lancet. Oncology | 2024

von Bamias, A. | Davis, I. | Galsky, M. | +21

9

Effect of antibiotic treatment on immune checkpoint inhibitors efficacy in patients with advanced non-small cell lung cancer

enthalten in: Lung cancer (Amsterdam, Netherlands) | 2023

von Alkan Şen, G. | Şentürk Öztaş, N. | Değerli, E. | +3

10

First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1) : 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial

enthalten in: The Lancet. Oncology | 2023

von Özgüroğlu, M. | Kilickap, S. | Sezer, A. | +21

ErratumIn: Lancet Oncol. 2023 Oct;24(10):e405. - PMID 37797644

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[19]